Browsing Tag
Zepbound
27 posts
Zepbound outperforms Wegovy in SURMOUNT-5 trial: Eli Lilly’s weight-loss drug achieves 47% greater relative reduction
Zepbound outperforms Wegovy with 20.2% weight loss in SURMOUNT-5 trial. See how Eli Lilly’s stock and investor sentiment responded to this clinical milestone.
More affordable Zepbound? Lilly’s new pricing plan shakes up obesity treatment
Eli Lilly and Company (Lilly) has introduced new single-dose vials of Zepbound (tirzepatide), expanding treatment options for self-pay…
Eli Lilly sets 2024 revenue at $45bn amid revised guidance
Eli Lilly and Company, a leading global pharmaceutical firm, has adjusted its 2024 revenue forecast to $45 billion,…
Eli Lilly’s stock plummets over missed sales forecasts for Mounjaro, Zepbound – what’s next for the pharma giant?
Eli Lilly & Co. has faced a dramatic drop in its stock price, tumbling over 10% following a…
This diabetes breakthrough drug slashes risk by 94%—discover how tirzepatide is transforming obesity treatment
Eli Lilly and Company (NYSE: LLY) has released compelling results from the SURMOUNT-1 study, which highlights that tirzepatide…
Lilly’s Zepbound marks remarkable weight loss milestone in SURMOUNT-4 study
In a significant development in the field of obesity treatment, Lilly’s Zepbound (tirzepatide) has shown remarkable results in…
Lilly bags Zepbound FDA approval for obesity treatment
The U.S. Food and Drug Administration has granted approval to Eli Lilly’s Zepbound (tirzepatide) injection, making it the…